CLIN CHEM LAB MED:三种分析方法比较肌萎缩性侧索硬化症、额颞叶痴呆和对照组中血清和CSF pNfH水平的相关性

2019-11-17 MedSci MedSci原创

磷酸化神经丝H(pNfH)是一种神经元细胞骨架蛋白,它可能为神经退行性疾病(NDDs)的神经元损伤提供一种有前途的血液生物标志物。然而,目前测量pNfH水平以及血清水平是否与NDDs中脑脊液(CSF)水平相关的最佳分析方法仍有待进一步研究。

磷酸化神经丝H(pNfH)是一种神经元细胞骨架蛋白,它可能为神经退行性疾病(NDDs)的神经元损伤提供一种有前途的血液生物标志物。然而,目前测量pNfH水平以及血清水平是否与NDDs中脑脊液(CSF)水平相关的最佳分析方法仍有待进一步研究。

在这里,研究人员比较了三种新的分析方法(自制Simoa、商用SimoaELISA)的分析灵敏度和可靠性,以量化肌萎缩性脊髓侧索硬化症(ALS)、额颞叶痴呆(FTD)和对照受试者脑脊液和血清中的pNfH

研究显示,三种检测方法均呈高度相关的脑脊液测定,Simoa试验对血清测定结果也有较高的相关性(ϱ = 0.95)。血清水平与脑脊液水平密切相关(均为ϱ = 0.62)。这三种检测方法都可以通过脑脊液pNfH水平的升高来区分ALS和对照组,Simoa也可以通过血清pNfH水平的升高来区分ALS和对照组。pNfH水平在FTD中也有升高。

如果用Simoa测定脑脊液中pNfH的浓度,血液pNfH的浓度可能为神经元损伤提供一个敏感和可靠的生物标志物,具有良好的检测间相关性。Simoa检测的血清pNfH水平与脑脊液水平密切相关,使血清pNfH成为NDDs神经损伤的一种容易获得的血液生物标志物。

原始出处:

Carlo WilkeFani Pujol-CalderónCorrelations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-12-17 chendoc252
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-02-01 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-03-25 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-06-22 kcb078
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1695912, encodeId=a1621695912f7, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 17 05:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744290, encodeId=29711e44290e3, content=<a href='/topic/show?id=d6df58e8151' target=_blank style='color:#2F92EE;'>#方法比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58781, encryptionId=d6df58e8151, topicName=方法比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f8535318348, createdName=gous, createdTime=Sat Feb 01 14:21:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775483, encodeId=40341e75483fc, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 25 19:21:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942299, encodeId=daac19422995e, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 10:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668862, encodeId=36dc16688627d, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Mon Jun 22 11:21:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837751, encodeId=2fee183e7516e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Dec 09 11:21:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046207, encodeId=521a204620ed6, content=<a href='/topic/show?id=ec704665384' target=_blank style='color:#2F92EE;'>#对照组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46653, encryptionId=ec704665384, topicName=对照组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Mon Mar 09 07:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983086, encodeId=e9341983086ce, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 20 07:21:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503126, encodeId=3f591503126a2, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610133, encodeId=4e88161013316, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:21:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]

相关资讯

Neurology:脑室出血后的CSF炎症反应

脑室出血(IVH)常导致死亡和不良功能预后。动物实验和临床研究显示CSF炎症反应与IVH有关,表现为细胞数、蛋白和糖的变化。这种变化的预期时间过程和它与出血量大小的关系尚不清楚,在细菌感染的情况下也不清楚IVH对CSF炎症判断的影响。当脑室内注入溶栓剂以加速清除IVH时,这种治疗方法对炎症反应的作用也存在矛盾的报道。

JAMA Neurol:脑脊液神经丝轻蛋白与神经系统疾病诊断

CNFL作为神经轴索损伤的生物标志物对中枢神经系统疾病的诊断具有一定的价值

Neurology:脑淀粉样血管病患者CSF生物标志物概况分析!

由此可见,Aβ42、Aβ40、t-tau和p-tau的特异性CSF模式可能是CAA的分子生物标志物,但需要在更大的CAA队列中进行分析。

Neurology:巨大蛛网膜颗粒是高颅压的因还是果?

16岁,男孩。反复一过性视力丧失,双侧视乳头水肿。MRI 显示双侧横窦巨大蛛网膜颗粒(giant arachnoid granulations,GAG),高颅压征象(下图)。CSF 压力420 mmH2O。腰穿大量放脑脊液后(After depletive lumbar puncture),GAG 缩小,静脉窦官腔狭窄缓解(下图)。轴位 T2加权相显示视神经迂曲(箭头,A 图)。轴位(B 图)和额

Stroke:蛛网膜下腔出血严重损害非人灵长类动物脑实质脑脊液循环!

CSF主动渗透入多脑回动物大脑脑实质内,正如啮齿动物中描述的类淋巴系统。这种实质性CSF循环可被SAH严重损伤。

JAMA:CSF非培养感染检测在免疫功能正常的儿童中很常见,但阳性结果很少

脑脊液(CSF)非培养感染检测对免疫能力正常且细胞计数正常的儿童有何价值?这项横断面研究调查了一家大型学术性三级护理儿童医院的电子病历系统中的筛选和诊断检测,回顾了2007年7月1日至2016年12月31日在医院住院或门诊进行腰椎穿刺(4811次手术)的0.5岁至18.9岁儿童的记录。有留置的CSF分流器或导管的患者、现患有或有病史的肿瘤、免疫或风湿病的患者、服用免疫抑制药物的患者被排除。4083